Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma

International Journal of Cancer

Volumn 129, Issue 7, 2011, Pages 1576-1585

  Sunagozaka, Hajime ^a   Honda, Masao ^a   Yamashita, Taro ^a   Nishino, Ryuhei ^a   Takatori, Hajime ^a   Arai, Kuniaki ^a   Yamashita, Tatsuya ^a   Sakai, Yoshio ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

c19orf10; hepatocellular carcinoma; serial analysis of gene expression

Indexed keywords

ALPHA FETOPROTEIN; C19ORF10 PROTEIN; INTERLEUKIN 25; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SECRETORY PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; C19ORF10 GENE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; LIVER CELL CARCINOMA; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA INTERFERENCE; SERIAL ANALYSIS OF GENE EXPRESSION;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKINS; LIVER NEOPLASMS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 79960908857     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25830     Document Type: Article

References (41)

1. Befeler AS, Di Bisceglie AM,. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-19. (Pubitemid 34533556)
2. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T,. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801. (Pubitemid 23174709)
3. Liang TJ, Jeffers LJ, Reddy KR, De Medina M, Parker IT, Cheinquer H, Idrovo V, Rabassa A, Schiff ER,. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993; 18: 1326-33. (Pubitemid 23348417)
4. Mayans MV, Calvet X, Bruix J, Bruguera M, Costa J, Esteve J, Bosch FX, Bru C, Rodes J,. Risk factors for hepatocellular carcinoma in Catalonia, Spain. Int J Cancer 1990; 46: 378-81. (Pubitemid 20291088)
5. Mohamed AE, Kew MC, Groeneveld HT,. Alcohol consumption as a risk factor for hepatocellular carcinoma in urban southern African blacks. Int J Cancer 1992; 51: 537-41.
6. Smedile A, Bugianesi E,. Steatosis and hepatocellular carcinoma risk. Eur Rev Med Pharmacol Sci 2005; 9: 291-3. (Pubitemid 41387394)
7. Floreani A, Baragiotta A, Baldo V, Menegon T, Farinati F, Naccarato R,. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology 1999; 29: 1425-8. (Pubitemid 29211043)
8. Tradati F, Colombo M, Mannucci PM, Rumi MG, De Fazio C, Gamba G, Ciavarella N, Rocino A, Morfini M, Scaraggi A, Taioli E,. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998; 91: 1173-7. (Pubitemid 28086869)
9. Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF,. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26: 1138-42. (Pubitemid 27509294)
10. Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J,. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001; 96: 1160-3. (Pubitemid 32319154)
11. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-81. (Pubitemid 29364999)
12. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL,. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330-5. (Pubitemid 30078596)
13. Peterson MS, Baron RL,. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 123-44. (Pubitemid 32118642)
14. Choi BI,. The current status of imaging diagnosis of hepatocellular carcinoma. Liver Transpl 2004; 10: S20-S25. (Pubitemid 38240095)
15. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K,. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62 (Suppl 1): 57-63. (Pubitemid 34702021)
16. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS,. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990; 11: 481-8.
17. Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y,. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002; 49: 235-8. (Pubitemid 34289526)
18. Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H, Hayashi E, Ogihara T, Kamada T,. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993; 38: 2170-6. (Pubitemid 24035747)
19. Yamashita T, Honda M, Kaneko S,. Application of serial analysis of gene expression in cancer research. Curr Pharm Biotechnol 2008; 9: 375-82.
20. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
22. Yamashita T, Hashimoto S, Kaneko S, Nagai S, Toyoda N, Suzuki T, Kobayashi K, Matsushima K,. Comprehensive gene expression profile of a normal human liver. Biochem Biophys Res Commun 2000; 269: 110-16.
23. Yamashita T, Honda M, Takatori H, Nishino R, Hoshino N, Kaneko S,. Genome-wide transcriptome mapping analysis identifies organ-specific gene expression patterns along human chromosomes. Genomics 2004; 84: 867-75. (Pubitemid 39314447)
24. Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T, Kaneko S,. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol 2009; 50: 100-10.
25. Yamashita T, Kaneko S, Hashimoto S, Sato T, Nagai S, Toyoda N, Suzuki T, Kobayashi K, Matsushima K,. Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem Biophys Res Commun 2001; 282: 647-54. (Pubitemid 32917921)
26. Tulin EE, Onoda N, Nakata Y, Maeda M, Hasegawa M, Nomura H, Kitamura T,. SF20/IL-25, a novel bone marrow stroma-derived growth factor that binds to mouse thymic shared antigen-1 and supports lymphoid cell proliferation. J Immunol 2001; 167: 6338-47. (Pubitemid 33081565)
27. Tulin EE, Onoda N, Nakata Y, Maeda M, Hasegawa M, Nomura H, Kitamura T,. SF20/IL-25, a novel bone marrow stroma-derived growth factor that binds to mouse thymic shared antigen-1 and supports lymphoid cell proliferation. J Immunol 2003; 170: 1593. (Pubitemid 36139532)
28. Wang P, Mariman E, Keijer J, Bouwman F, Noben JP, Robben J, Renes J,. Profiling of the secreted proteins during 3T3-L1 adipocyte differentiation leads to the identification of novel adipokines. Cell Mol Life Sci 2004; 61: 2405-17. (Pubitemid 39382030)
29. Weiler T, Du Q, Krokhin O, Ens W, Standing K, El-Gabalawy H, Wilkins JA,. The identification and characterization of a novel protein, c19orf10, in the synovium. Arthritis Res Ther 2007; 9: R30.
30. Takatori H, Yamashita T, Honda M, Nishino R, Arai K, Takamura H, Ohta T, Zen Y, Kaneko S,. dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma. Liver Int 2010; 30: 438-46.
31. Sakai Y, Honda M, Fujinaga H, Tatsumi I, Mizukoshi E, Nakamoto Y, Kaneko S,. Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients. Cancer Res 2008; 68: 10267-79.
32. Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S,. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 2006; 44: 1122-38. (Pubitemid 44748364)
33. Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC,. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 2004; 64: 8022-8. (Pubitemid 39446938)
34. Sakai Y, Kaneko S, Nakamoto Y, Kagaya T, Mukaida N, Kobayashi K,. Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma. Cancer Gene Ther 2001; 8: 695-704. (Pubitemid 32983125)
35. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J,. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97. (Pubitemid 36799110)
36. Hodo Y, Hashimoto S, Honda M, Yamashita T, Suzuki Y, Sugano S, Kaneko S, Matsushima K,. Comprehensive gene expression analysis of 5′-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma. Genomics 2010; 95: 217-23.
37. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84. (Pubitemid 41464706)
38. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42. (Pubitemid 38702844)
39. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32. (Pubitemid 41058344)
40. Llovet JM, Bruix J,. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-27.
41. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C,. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-8. (Pubitemid 46094197)